Genomics is at an inflection point. Dramatic declines in sequencing costs and significant advances in our understanding of the genome means we’re moving closer to a world where genomics is the standard of care. Evidence is emerging that population-level screening drives meaningful clinical impact with ~1 in 30 people having an actionable result, but up to 90% of them are missed under current guidelines. Leading health systems are working to solve this by offering broad genetic screening to their communities. But questions remain about how to handle results when millions of people are screened. The tools and services to enable this are critical, including patient- and physician-friendly results, educational materials, and genetic counseling. In this session, healthcare leaders will discuss how they scale return of results and improve outcomes for their communities.
Justin is a co-founder and SVP of Business Development & Strategy at Helix, a population genomics company with a mission to empower every person to improve their life through DNA. Helix’s end-to-end population health solution enables health systems to integrate genomic information on a population scale to improve outcomes, lower costs, increase patient engagement, and accelerate research. Prior to Helix, Justin was a Vice President in the healthcare group at Warburg Pincus, a global private equity firm focused on growth investing. Earlier in his career, he also spent time at the Boston Consulting Group, where he worked with a variety of companies in the tech and healthcare industries, and Onyx Pharmaceuticals. Justin holds a B.S. in Chemical Engineering and a M.S. in Bioengineering from Stanford University. He also received a J.D. from Stanford Law School and an M.B.A. from Stanford Graduate School of Business, where he was an Arjay Miller Scholar.
Trained in human genetics, Dr. Willard has focused his research, educational, and leadership interests at the crossroads of basic genetics and genome biology and their impact on society and the practice of medicine. His research group's efforts on the function of the human genome led to the identification of the XIST non-coding RNA gene that controls X chromosome inactivation and to the genomic definition of human centromeres, comprised of complex repetitive DNA sequences that form specialized heterochromatin underlying chromosome segregation in mitosis and meiosis. He has led complex interdisciplinary units that combined both basic genetics and medical genetics at major universities and hospitals and, at various institutions, started new degree programs in genetics/genomics, genetic counseling, bioinformatics, and genome policy. He is co-author of the textbook Genetics in Medicine, and co-editor of the Genomic and Precision Medicine book series. He is an elected member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts & Sciences. Prior to coming to Geisinger full-time, he was chair of the Geisinger Scientific Advisory Board from 2011-2017.
Teresa Kruisselbrink is the Genetic Counselor Supervisor in the Mayo Clinic Center for Individualized Medicine. She began her career in 1997 at Mayo Clinic by establishing the role of the laboratory-based genetic counselor in Molecular Genetics, Biochemical Genetics, Cytogenetics, and Maternal Serum Screening. She has provided genetic counseling in Medical Genetics, Neurology, Obstetrics, Cardiology and outreach clinics. Ms. Kruisselbrink contributes to numerous educational programs including Mayo Medical School, Graduate School, and fellowship and residency programs in the laboratory and clinical environments. She is also actively involved in mentoring high school and college students wishing to pursue a career in genetic counseling. Teresa received her BS in Molecular, Cellular, Developmental Biology, and Genetics and MS in Genetic Counseling from the University of Minnesota. She is an Instructor of Laboratory Medicine and Pathology.